Strontium ranelate in the treatment of postmenopausal osteoporosis: results of administration in clinical practice
https://doi.org/10.14412/1995-4484-2008-655
Abstract
Strontium ranelate (Bivalos) is a new drug with dual mechanism of action for the treatment of postmenopausal osteoporosis (OP) Objective. To assess efficacy and tolerability of bivalos in women with postmenopausal osteoporosis in a one year multicentre open study. Material and methods. 60 postmenopausal women (mean age 63,6+5,7 years) with spine OP (mean T-criterion -3,1 ±0,4 SD) received strontium ranelate2 g/day during a year. 5 visits were performed (scrining, inclusion, 3, 6 and 12 months). Markers of bone metabolism were evaluated at inclusion, 3 and 12 months. Densitometry was performed at scrining and after 12 months. At all visits pain in spine was assessed with a 5 point scale and adverse events were recorded. Results. BMD increase in lumbar spine was +4,68%, in femur neck - +2% and in general femur value — +3,1% after 12 months of treatment (p<0,01) in comparison with baseline level. Among pt completed the treatment BMD increase in spine above 2% was achieved in 78% of pt. In 41% from them it exceed 6%. BMD increase in femur neck above 2% was achieved in 41% and in general femur value — in 67% of pts. 11% of pts showed deterioration in studied skeleton regions and did not respond to the therapy. During the treatment osteogenesis marker increased by 19,6% and bone resorption marker decreased by 16,7%. Adverse events related to strontium ranelate administration appeared in 9 (15%) pts including diarrhea, leg spasms, myalgia, shortness of breath and dry cough, nausea, gastric ulcer exacerbation. The drug was withdrawn due to adverse eventsin only 3 (5%).
About the Authors
N V ToroptsovaO A Nikitinskaya
T A Korotkova
N V Demin
A V Smirnov
L I Benevolenskaya
L Y Rozinskaya
S. S. Rodionova
References
1. <div><p>Arnaud C.D., Zanchetta J. R. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Eng. J. Med., 2001, 344, 1434-1441.</p><p>Black D.M., Cummings S.R., Karpf D.B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebra! fractures. Lancet, 1996, 348, 1535-1541.</p><p>Boivin G.Y., Chavassieux P.M., Sandora A.C. et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone, 2000, 27, 687-694.</p><p>Bruyere O., Delmas P.D., Devogelaer J-P. et al. Relations between increase in femoral neck bone mineral density and decrease in hip fracture incidence during treatment with strontium ranelate. Osteoporosis Int., 2006, 17(suppl. 1), 96.Abstr. 6th Europ. Congr. on Clin, and Econom. Aspects Osteopor. and Osteoarthr. - ECCEO 6, 15-18 March 2006, Vienna, Austria.</p><p>Bruyere O., Roux C., Cannata J.B., et al. Associations between increase in bone mineral density and decrease in clinical vertebral fracture incidence during a treatment with strontium ranelate. Osteoporosis Int., 2006, 17, (suppl. 1.), 8.</p><p>Buechler J., Chappuis P., Saffar J.L. et al. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone, 2001, 29, 176-179.</p><p>Chavassieux P.M., Arlot M.E., Red a C. et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Investig., 1997, 100, 1475-1480.</p><p>Ettinger B., Black D.M. , Mitlak B.H. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treatment with raloxifene: results from a 3-year randomized clinical trial. JAMA, 1999, 282, 637-645.</p><p>Merie P.J. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate. Osteoporosis Int., 2003, 14, S9-S12.</p><p>Meunier P.J., Slosman D.O., Delmas P.D. et al. Stivntium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis — a 2 — year randomized placebo controlled trial. J. Clin. Endocrinol. Metabol., 2002, 87, 2060-2066.</p><p>Meunier P.J., Roux C., Seeman E. et al. The effects of strontium Ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl. J. Med., 2004, 350, 459-468.</p><p>Meunier P.J., Arlot M.E., Roux C. et al. How to rebalance bone turnover in favor offormation. Osteoporosis Int., 2006, 17(suppl. I), 114.</p><p>Register JY, Meunier PJ. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporosis Int., 2003, 14. (suppl. 3), S56-S65.</p><p>Register J. Y., Seeman E., De Vernejout M.C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrin. Metabol., 2005, 90, 2816-2822.</p><p>Register J. Y., Sarlet N. Lejeune E. et al. Stivntium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action. J. Curr. Osteoporosis Rep., 2005, 1, 30-34.</p><p>RouxC., Register J. Y, Fechtenbaum J. etal. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J. Bone Miner. Res., 2006, Online published January, 22.</p><p>Seeman E. Pathogenesis of bone fragility in women and men. Lancet, 2002, 359, 1841-1850.</p></div><br />
Review
For citations:
Toroptsova N.V., Nikitinskaya O.A., Korotkova T.A., Demin N.V., Smirnov A.V., Benevolenskaya L.I., Rozinskaya L.Y., Rodionova S.S. Strontium ranelate in the treatment of postmenopausal osteoporosis: results of administration in clinical practice. Rheumatology Science and Practice. 2008;46(3):23-29. (In Russ.) https://doi.org/10.14412/1995-4484-2008-655
Views:
1079
Email this article 